leadf
logo-loader
RNS
viewHikma Pharmaceuticals PLC

Hikma Pharmaceutical - Block listing Interim Review

RNS Number : 2475E
Hikma Pharmaceuticals Plc
16 October 2018
 

 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

LEI: 549300BNS685UXH4JI75

 

Date: 16 October 2018

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

&

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From:

1 April 2018

To:

30 September 2018

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 107,061 ordinary shares of 10 pence

MIP: 978,116 ordinary shares of 10 pence

EIP: 1,092,242 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

EIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

LTIP: 4,347 ordinary shares of 10 pence

MIP: 192,956 ordinary shares of 10 pence

EIP:  377,718 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 102,714 ordinary shares of 10 pence

MIP: 785,160 ordinary shares of 10 pence

EIP: 714,524 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2018

-

-

792,700

Blocklisting return on 01/04/18

 

Block Listing Six Monthly Return

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2018

-

-

107,061

Blocklisting return on 01/04/18

31/08/2018


4,347

102,714


 

Block Listing Six Monthly Return

Management Incentive Plan ("MIP")

Date

Block

Listing

Shares

Issued

 Balance

 (Headroom)

Notes

 

01/04/2018

 

0

 

                          0

 

978,116

Blocklisting return on 01/04/18

19/04/2018

0

1,096

977,020


11/05/2018

0

2,118

974,902


11/05/2018

0

4,407

970,495


14/05/2018

0

1,485

969,010


16/05/2018

0

172,195

796,815


18/05/2018

0

910

795,905


21/05/2018

0

551

795,354


29/05/2018

0

1,660

793,694


29/05/2018

0

759

792,935


06/06/2018

0

764

792,171


06/06/2018

0

1,341

790,830


06/06/2018

0

1,323

789,507


28/08/2018

0

2,027

787,480


06/09/2018

0

1,903

785,577


20/09/2018

0

417

785,160


 

Block Listing Six Monthly Return

 

Executive Incentive Plan ("EIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2018

0

0

1,092,242

Blocklisting return on 01/04/18

02/04/2018

0

58,010

1,034,232


12/04/2018

0

7,367

1,026,865


16/05/2018

0

46,224

980,641


16/05/2018

0

69,297

911,344


16/05/2018

0

40,000

871,344


23/05/2018

0

5,493

865,851


23/05/2018

0

132,439

733,412


31/08/2018

0

5,374

728,038


12/09/2018

0

6,514

 

714,524


 

 


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRGGGBPUUPRGAQ

Quick facts: Hikma Pharmaceuticals PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read